SeaSpine to Report First Quarter 2017 Financial Results on

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
137
SeaSpine to Report First Quarter 2017 Financial Results on May 4, 2017

CARLSBAD, Calif., April 21, 2017 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE ), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today that it will release first quarter 2017 financial results after the close of trading on Thursday, May 4, 2017.  The Company’s management team will host a corresponding conference call beginning at 1:30pm PT/4:30pm ET to discuss the financial results and recent business developments.

Individuals interested in listening to the conference call may do so by dialing (877) 418-4766 for domestic callers or (614) 385-1253 for international callers, using Conference ID: 2407268. The webcast will also be available on the SeaSpine website following the completion of the call. To listen to the webcast, please visit the investor relations section of the SeaSpine website at www.seaspine.com.

About SeaSpine

SeaSpine is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal hardware solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine's orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures.  SeaSpine's spinal hardware portfolio consists of an extensive line of products to facilitate spinal fusion in minimally invasive surgery (MIS), complex spine, deformity and degenerative procedures. Expertise in both orthobiologic sciences and spinal fusion hardware product development helps SeaSpine to offer its surgeon customers a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in over 30 countries worldwide.

Investor Relations Contact Lynn Pieper Lewis (415) 937-5402 ir@seaspine.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Madrigal Pharmaceuticals Rewards New Employees with Equity Awards

Updated Category News Views 100

Overview of Equity Inducement Awards Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a leading biopharmaceutical organization, has recently initiated equity inducement awards to welcome new talent to its dynamic team. This initiative demonstrates Madrigal's commitment to fostering a strong workforce geared towards tackling significant health challenges related to metabolic...

Continue Reading
Boston Metal Welcomes Roy Harvey to Enhance Board Leadership

Updated Category News Views 202

Boston Metal Appoints Industry Leader Roy Harvey Boston Metal, a prominent technology company that is transforming the landscape of global metals production, has made a significant move by appointing Roy Harvey to its Board of Directors. This decision is pivotal as Boston Metal gears up for the commercial rollout of its groundbreaking Molten Oxide Electrolysis (MOE)...

Continue Reading
RBL LLC Partners with Carnrite Ventures for Biotech Growth

Updated Category News Views 125

RBL LLC Partners with Carnrite Ventures for Biotech Growth RBL LLC, a leading biotech venture creation studio, is excited to announce a significant investment from Carnrite Ventures. This partnership aims to enhance the rapid development of their robust pipeline of innovative therapeutic companies. According to Paul Wotton, the managing partner at RBL, "Carnrite's...

Continue Reading
OncoC4 and AcroImmune Merger: A Milestone in Immunotherapy

Updated Category News Views 106

Introducing the OncoC4 and AcroImmune Merger OncoC4, Inc. has just announced a thrilling merger with AcroImmune, a strategic union that promises to significantly boost OncoC4's standing in the biopharmaceutical sector. This collaboration brings together two companies dedicated to pioneering advancements in cancer treatment, with a special focus on developing unique...

Continue Reading
Rezolve AI Celebrates Major Investment Transforming AI Landscape

Updated Category News Views 92

Rezolve AI Excited About $30 Billion AI Investment Rezolve AI (NASDAQ: RZLV), well-known for its cutting-edge AI-driven commerce solutions, is enthusiastic about the recent announcement from Microsoft and BlackRock. These influential tech companies plan to invest $30 billion into AI infrastructure, a decision that could profoundly alter the landscape of the artificial...

Continue Reading